Tabula Rasa HealthCare (TRHC) Given Daily Media Impact Score of 0.05
Headlines about Tabula Rasa HealthCare (NASDAQ:TRHC) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tabula Rasa HealthCare earned a news impact score of 0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.9558839032149 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Tabula Rasa HealthCare Inc (TRHC) Major Shareholder Sells $17,686,053.00 in Stock (americanbankingnews.com)
- Tabula Rasa HealthCare Named Best Performing IPO Among Top 50 Digital Health Companies in 2017 (finance.yahoo.com)
- Is Tabula Rasa Healthcare Inc’s (undefined:TRHC) Balance Sheet Strong Enough To Weather A Storm? (finance.yahoo.com)
- Insider Selling: Tabula Rasa HealthCare Inc (TRHC) Director Sells 15,000 Shares of Stock (americanbankingnews.com)
- Insider Selling: Tabula Rasa HealthCare Inc (TRHC) Insider Sells 123,000 Shares of Stock (americanbankingnews.com)
Several equities analysts recently commented on TRHC shares. UBS upped their target price on shares of Tabula Rasa HealthCare from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, August 30th. Wells Fargo & Company lowered shares of Tabula Rasa HealthCare from an “outperform” rating to a “market perform” rating and boosted their price target for the company from $17.00 to $21.00 in a report on Thursday, September 7th. Piper Jaffray Companies reissued an “overweight” rating and issued a $29.00 price target (up previously from $20.00) on shares of Tabula Rasa HealthCare in a report on Wednesday, September 20th. ValuEngine raised shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Finally, Zacks Investment Research raised shares of Tabula Rasa HealthCare from a “hold” rating to a “strong-buy” rating and set a $31.00 price target on the stock in a report on Wednesday, October 11th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $28.25.
Shares of Tabula Rasa HealthCare (NASDAQ TRHC) traded down $0.73 during trading on Wednesday, reaching $27.86. 241,900 shares of the company’s stock traded hands, compared to its average volume of 106,561. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.66 and a current ratio of 0.73. Tabula Rasa HealthCare has a 12-month low of $11.59 and a 12-month high of $36.80.
Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.02. The firm had revenue of $33.27 million for the quarter, compared to analyst estimates of $31.76 million. Tabula Rasa HealthCare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.06 EPS. analysts expect that Tabula Rasa HealthCare will post 0.05 EPS for the current fiscal year.
In other news, Director Bruce Luehrs sold 269,000 shares of the company’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $25.85, for a total value of $6,953,650.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Orsula V. Knowlton sold 8,000 shares of the company’s stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $26.68, for a total transaction of $213,440.00. The disclosure for this sale can be found here. Insiders sold a total of 1,099,180 shares of company stock worth $28,435,203 in the last three months. Insiders own 45.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Tabula Rasa HealthCare (TRHC) Given Daily Media Impact Score of 0.05” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/tabula-rasa-healthcare-trhc-given-daily-media-impact-score-of-0-05/1761635.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with Analyst Ratings Network's FREE daily email newsletter.